Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use. The availability of these radionuclides is often constrained by the intricate production processes and purification, as well as regulatory and logistical challenges.

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [Sm]Sm-DOTA-TATE.

Samarium-153 is a promising theranostic radionuclide, but low molar activities (Am) resulting from its current production route render it unsuitable for targeted radionuclide therapy (TRNT). Recent efforts combining neutron activation of 152Sm in the SCK CEN BR2 reactor with mass separation at CERN/MEDICIS yielded high-Am 153Sm. In this proof-of-concept study, we further evaluated the potential of high-Am 153Sm for TRNT by radiolabeling to DOTA-TATE, a well-established carrier molecule binding the somatostatin receptor 2 (SSTR2) that is highly expressed in gastroenteropancreatic neuroendocrine tumors.

Bifunctional chelators for radiorhenium: past, present and future outlook.

Targeted radionuclide therapy (TRNT) is an ever-expanding field of nuclear medicine that provides a personalised approach to cancer treatment while limiting toxicity to normal tissues. It involves the radiolabelling of a biological targeting vector with an appropriate therapeutic radionuclide, often facilitated by the use of a bifunctional chelator (BFC) to stably link the two entities. The radioisotopes of rhenium, Re ( = 90 h, 1.

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of Stability.

Targeted radionuclide therapy (TRNT) is a promising approach for cancer therapy. Terbium has four medically interesting isotopes (Tb, Tb, Tb and Tb) which span the entire radiopharmaceutical space (TRNT, PET and SPECT imaging). Since the same element is used, accessing the various diagnostic or therapeutic properties without changing radiochemical procedures and pharmacokinetic properties is advantageous.

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy.

Samarium-153 (Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. Sm has a half-life of 1.93 d and decays into a stable daughter nuclide (Eu) whereupon β particles [E = 705 keV (30%), 635 keV (50%)] are emitted which are suitable for therapy.

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with Bi are discussed in this review, covering the entire chain from radionuclide production to bedside.

Improved antiparasitic activity by incorporation of organosilane entities into half-sandwich ruthenium(II) and rhodium(III) thiosemicarbazone complexes.

A series of ferrocenyl- and aryl-functionalised organosilane thiosemicarbazone compounds was obtained via a nucleophilic substitution reaction with an amine-terminated organosilane. The thiosemicarbazone (TSC) ligands were further reacted with either a ruthenium dimer [(η(6-i)PrC6H4Me)Ru(μ-Cl)Cl]2 or a rhodium dimer [(Cp*)Rh(μ-Cl)Cl]2 to yield a series of cationic mono- and binuclear complexes. The thiosemicarbazone ligands, as well as their metal complexes, were characterised using NMR and IR spectroscopy, and mass spectrometry.

trans-Dichloridobis[diphen-yl(thio-phen-2-yl)phosphane-κP]palladium(II).

The title compound, trans-[PdCl(2)(C(16)H(13)PS)(2)], forms a monomeric complex with a trans-square-planar geometry. The Pd-P bond lengths are 2.3387 (11) Å, as the Pd atom lies on an inversion point, while the Pd-Cl bond lengths are 2.

trans-Dichloridobis[dicyclo-hex-yl(phen-yl)phosphane-κP]palladium(II).

The title compound, [PdCl(2){P(C(6)H(11))(2)(C(6)H(5))}(2)], forms a monomeric complex with a trans-square-planar geometry. The Pd-P bond lengths are 2.3343 (5) Å, as the Pd atom lies on an inversion centre, while the Pd-Cl bond lengths are 2.

Triethyl-ammonium hexa-μ(2)-acetato-κO:O'-diacetato-κO-aqua-μ(3)-oxido-triferrate(III) toluene monosolvate.

The title compound, (C(6)H(16)N)[Fe(3)(CH(3)CO(2))(8)O(H(2)O)]·C(7)H(8), was serendipitously crystallized from a reaction of disilanol with iron(II) acetate. The trinuclear acetatoferrate(III) anion has a triethyl-ammonium cation as the counterion. The three Fe atoms lie on the vertices of a regular triangle and are octa-hedrally coordinated.

trans-Carbonyl-chloridobis[tris-(4-chloro-phen-yl)phosphane]rhodium(I) acetone monosolvate.

The title compound, trans-[RhCl(C(18)H(12)Cl(3)P)(2)(CO)]·C(3)H(6)O, contains an Rh(I) atom in a distorted square-planar coordination with a P-Rh-P angle of 175.27 (2)° and Rh-P bond lengths of 2.3127 (4) and 2.

Bis(dicyclo-hexyl-phenyl-phosphine)silver(I) nitrate.

The title compound, [Ag(C(18)H(27)P)(2)]NO(3), is a mononuclear salt species in which the Ag atom is coordinated by two phosphine ligands, forming a cation, with the nitrate as the counter-anion, weakly inter-acting with the Ag atom, resulting in Ag⋯O distances of 2.602 (6) and 2.679 (6) Å.